No results for ‘’
Nectar Lifescience Ltd
₹11.44
(1.63%)
Sat, 20 Jun 2026, 02:27 pm
Health Technology
Pharmaceuticals: Major
24.5KNectar Lifescience Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.47 | 6.50 | 5.59 | 4.45 | 8.44 | 5.20 | 7.35 | 4.10 | 8.74 | 12.51 | 15.70 | 14.25 | 11.35 | 8.06 | 6.98 | 0 | 21.53 | 0 | 135.20 | 0 |
| Price to book ratio | 1.99 | 0.97 | 1.08 | 0.57 | 1.31 | 0.74 | 0.69 | 0.40 | 0.59 | 0.86 | 0.89 | 0.78 | 0 | 0.35 | 0.20 | 0.39 | 0.50 | 0.33 | 0.63 | 0.54 |
| Price to sales ratio | 1.39 | 0.68 | 0.57 | 0.32 | 0.93 | 0.51 | 0.41 | 0.22 | 0.33 | 0.50 | 0.51 | 0.48 | 0.32 | 0.14 | 0.09 | 0.27 | 0.32 | 0.23 | 0.40 | 0.31 |
| Price to cash flow ratio | 0 | 45.65 | 2.78 | 2.25 | 0 | 0 | 7.20 | 1.34 | 4.22 | 21.39 | 16.66 | 8.96 | 0 | 3.95 | 1.37 | 0 | 29.83 | 6.36 | 4.50 | 5.35 |
| Enterprise value | 498Cr | 681Cr | 877Cr | 905Cr | 1351Cr | 1299Cr | 1556Cr | 1224Cr | 1391Cr | 1718Cr | 1777Cr | 1654Cr | 1538Cr | 1265Cr | 979Cr | 1295Cr | 1381Cr | 1092Cr | 1290Cr | 1078Cr |
| Enterprise value to EBITDA ratio | 8.18 | 8.42 | 6.92 | 6.40 | 6.88 | 5.80 | 6.79 | 4.22 | 4.83 | 6.46 | 7.40 | 7.32 | 6.46 | 4.74 | 4.41 | 11.62 | 8.67 | 19.84 | 8.35 | 0 |
| Debt to equity ratio | 0.84 | 1.91 | 1.71 | 2.32 | 0.97 | 1.10 | 1.33 | 1.01 | 0.93 | 0.97 | 1.01 | 0.87 | 0.90 | 0.82 | 0.69 | 0.85 | 0.79 | 0.71 | 0.59 | 0.61 |
| Return on equity % | 28.26 | 21.69 | 29.61 | 18.04 | 19.98 | 15.37 | 9.73 | 10.38 | 6.92 | 7.03 | 5.67 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | -2.25 | 0.47 | -11.23 |
Nectar Lifescience Ltd Ratios
The Nectar Lifescience Ltd Ratios page provides a complete fundamental analysis of Nectar Lifescience Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Nectar Lifescience Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Nectar Lifescience Ltd (NSE: NECLIFE, BSE: 532649) is currently trading at ₹11.44, with a market capitalization of ₹223.4Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Nectar Lifescience Ltd remains a key stock for fundamental analysis using Nectar Lifescience Ltd Ratios.
Nectar Lifescience Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Nectar Lifescience Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Nectar Lifescience Ltd Ratios.
Historically, the Nectar Lifescience Ltd P/E ratio has shown strong fluctuations:
- 2024: 0
- 2023: 135.20
- 2022: 0
- 2021: 21.53
- 2020: 0
The decline in Nectar Lifescience Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Nectar Lifescience Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.54.
Historical P/B trend:
- 2024: 0.54
- 2023: 0.63
- 2022: 0.33
- 2021: 0.50
Nectar Lifescience Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Nectar Lifescience Ltd P/S ratio currently stands at 0.31, an important part of Nectar Lifescience Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 0.31
- 2023: 0.40
- 2022: 0.23
- 2021: 0.32
A stable or declining Nectar Lifescience Ltd P/S ratio indicates cautious market sentiment.
Nectar Lifescience Ltd Price to Cash Flow Ratio (P/CF)
The Nectar Lifescience Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 5.35.
Historical Nectar Lifescience Ltd Price to Cash Flow Ratio:
- 2024: 5.35
- 2023: 4.50
- 2022: 6.36
- 2021: 29.83
- 2020: 0
The rising Nectar Lifescience Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Nectar Lifescience Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Nectar Lifescience Ltd EV currently stands at ₹1078Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 1078Cr
- 2023: 1290Cr
- 2022: 1092Cr
- 2021: 1381Cr
Nectar Lifescience Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Nectar Lifescience Ltd EV/EBITDA ratio is currently 0, a key metric in Nectar Lifescience Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 0
- 2023: 8.35
- 2022: 19.84
- 2021: 8.67
Stable Nectar Lifescience Ltd EV/EBITDA indicates balanced valuation.
Nectar Lifescience Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Nectar Lifescience Ltd D/E ratio is currently 0.61, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.61
- 2023: 0.59
- 2022: 0.71
- 2021: 0.79
Nectar Lifescience Ltd maintains moderate leverage with manageable risk.
Return on Equity (ROE %)
The Nectar Lifescience Ltd ROE currently stands at -11.23%, showing profitability and capital efficiency.
Historical ROE:
- 2024: -11.23
- 2023: 0.47
- 2022: -2.25
- 2021: 2.33
Declining ROE indicates pressure on profitability.
Nectar Lifescience Ltd Ratios Analysis Summary
The Nectar Lifescience Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Nectar Lifescience Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Nectar Lifescience Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.